Isomorphic Labs raises $5 billion — six months after its previous $2.1 billion round
Isomorphic Labs, Demis Hassabis' drug company, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. The round was announced on Tuesday and is the company's first funding since Hassabis stepped down as CEO of Google DeepMind in August. But even as capital flows in, the company's central promise remains unresolved: In January, Hassabis said the first clinical trials were expected by the end of 2026 — now he no longer confirms a timeline, according to Bloomberg via The Next Web (ccd9a245).
The investor landscape
The round is broadly composed. Greenoaks and Sequoia Capital share leadership, and Andreessen Horowitz joins as a new investor, alongside several other unnamed new backers. All existing investors participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Alphabet, from which the company was spun out, is investing further with what Isomorphic itself calls a "continued significant investment". The company says the round was oversubscribed (ccd9a245).
Alphabet's participation is worth noting. It confirms that the parent company still sees the firm as a strategic bet, even as the sources do not fully specify the ownership structure — CNBC describes Isomorphic as a "startup founded by former Google DeepMind CEO Demis Hassabis", while The Next Web refers to it as "Alphabet's drug company" (ffe14dea, ccd9a245).
What is the valuation?
Isomorphic has not disclosed its valuation. Bloomberg reported earlier this month that the round would value the company at around $50 billion — but this is a projection from a single report, not a confirmed figure. Readers should therefore draw a sharp line between what is documented (the $5 billion round size and the investor list, which the company itself announced) and what is merely reported (ccd9a245).
The first round since the leadership shake-up
The round is Isomorphic's first since Hassabis in August stepped down as CEO of Google DeepMind as part of an Alphabet reorganisation. He is now chairman of DeepMind and Alphabet's chief scientist, but retains his position as CEO of Isomorphic Labs (ccd9a245).
The round also comes just six months after a $2.1 billion Series B in May (ccd9a245, 34dc844e). That investors oversubscribe such a large round so soon after an equally large financing and a leadership shake-up at the parent organisation suggests the market still places great trust in Hassabis and the AlphaFold platform.
What the money is for
Isomorphic says the capital will be used to further develop the company's drug design engine, IsoDDE, and to expand into more types of medicine (34dc844e).
The company claims IsoDDE is already producing positive preclinical results in its own programmes in oncology and immunology, as well as in collaborations with partners. Hassabis says there are more than 20 programmes underway, and the drug giants Eli Lilly, Novartis and Johnson & Johnson are listed as collaboration partners (ccd9a245). Note that the preclinical results are the company's own claims — they have not been independently verified.
Isomorphic was spun out of Google's DeepMind in 2021 and builds on AlphaFold, DeepMind's well-known protein structure model (34dc844e).
The open tension: the timeline
The biggest unanswered question is when the first clinical trials will actually begin. In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. Speaking to Bloomberg's Rebecca Torrence and Shirin Ghaffary, he would now not give an updated target. He said the company is "on track" with its regulatory submissions, and that more information will come in 2027 (ccd9a245).
The statement points toward a clinical start no earlier than 2027, but that is a reading of the wording, not a confirmed date. Hassabis told Bloomberg the money will accelerate the move toward clinical trials, and that the goal is to build a platform capable of developing hundreds of drugs per year (ccd9a245).
The stakes are serious for the company's valuation and promises: per Bloomberg, no regulator has yet approved an AI-designed drug (ccd9a245). Isomorphic thus remains a company that must prove its technical approach can deliver a fully developed drug candidate through regulatory approval.
What will settle the matter
Two things will bring clarity: an official valuation, which would verify or refute Bloomberg's reporting of around $50 billion — and a concrete date for the start of the first clinical trials, which Hassabis hinted may come during 2027. Until then, the story of Isomorphic Labs is a company with ever more capital and investor confidence, but with clinical proof still missing.

